Riskpilot← Back to searchSign inGet full accessSolna Läkarkonsult AB
ABActiveOrg 5591446652Polhemsgatan 18 B Lgh 1301General medical practice activities · NACE 8621Est. 20181 employees
Revenue 2025
SEK 178K
-32% vs 2024
EBITDA margin
89.6%
-32% vs 2024
Equity ratio
42.7%
Financial strength
Net profit 2025
SEK 207K
+43% vs 2024
| Revenue | SEK 178K | -32% |
| EBITDA | SEK 160K | -32% |
| Net profit | SEK 207K | +43% |
| Total assets | SEK 616K | -4% |
| Equity | SEK 263K | +34% |
| Employees | 1 | — |
Legal name
Solna Läkarkonsult AB
Org number
5591446652
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
10 januari 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamheten avser läkarkonsultation inom hälso- och sjukvård samt försäkringsärenden. I tjänsten ingår läkarundersökning, bedömning och förskrivning av läkemedel samt skriftliga utlåtanden och intyg. Företaget har kompetens inom specialistområdena psykiatri, rehabiliteringsmedicin, arbetsmedicin, internmedicin och försäkringsmedicin.
Address
Polhemsgatan 18 B Lgh 1301
Email
lindalongchen@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 28 | 276 | 264 | 178 |
| Staff expenses | — | — | −4 | −5 | −5 |
| EBITDA | −26 | 20 | 260 | 237 | 160 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −26 | 20 | 260 | 237 | 160 |
| Net financials | 63 | −4 | 0 | 9 | 15 |
| Profit before tax | 27 | 12 | 195 | 183 | 264 |
| Tax | −6 | −3 | −41 | −39 | −57 |
| Net profit | 21 | 9 | 154 | 144 | 207 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 655 | 434 | 566 | 641 | 616 |
| Equity | 436 | 245 | 212 | 196 | 263 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 54 | 20 | 120 | 149 | 147 |
| Total debt | 54 | 20 | 120 | 149 | 147 |
EBITDA margin
89.6%
This company
15.8%
Market median
+467% vs market
20212025
Equity ratio
42.7%
This company
38.2%
Market median
+12% vs market
20212025
Return on equity
78.6%
This company
18.4%
Market median
+327% vs market
20212025
Net profit margin
116.0%
This company
8.1%
Market median
+1332% vs market
20212025
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20212025
Debt / equity
1.34×
This company
0.62×
Market median
-116% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Solna Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Long-Long Zhe Chen | Deputy Board Member | 0 companies |
| Linda Xiue Hou | Board of Directors | 0 companies |
| David Xiaojun Chen | Deputy Board Member | 0 companies |
| Henry Chen | Deputy Board Member | 0 companies |